Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040768 · ClinicalTrials.gov registry record · Phase 2
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00040768: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00040768 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040768, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of bortezomib in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer. Bortezomib may interfere with the growth of tumor cells by blocking certain enzymes necessary for tumor cell growth
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2002-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040768
The ClinicalTrials.gov registry entry for NCT00040768 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00040768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00040768 about?
NCT00040768 is a clinical study titled "Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer". Phase II trial to study the effectiveness of bortezomib in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer. Bortezomib may interfere with the growth of tumor cells by blocking certain enzymes necessary for tumor cell growth
What is the current status of trial NCT00040768?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2002-04.
What interventions are being tested in trial NCT00040768?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00040768?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.